natgillin/translations-raw huggingface dataset:
If you see blood after you take the needle out of your skin, press the injection site lightly with a piece of gauze or swab.
Če opazite kri, ko potegnete iglo iz kože, narahlo pritisnite na mesto injiciranja s koščkom gaze ali z zložencem.
Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters.
V prvem trimesečju se lahko potreba po insulinu zmanjša, v drugem in tretjem trimesečju pa se praviloma poveča.
In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose.
Marsikdaj je indicirano testiranje urina za ketone in pogosto je treba prilagoditi odmerek insulina.
Do not throw it away.
Ne zavrzite je.
They can spread around the injection site.
Razširijo se lahko okoli mesta injiciranja.
The switch from one insulin therapy to another requires medical prescription, medical supervision and blood glucose monitoring.
Za prehod z enega zdravljenja z insulinom na drugega so potrebni zdravnikov recept, zdravniški nadzor in spremljanje glukoze v krvi.
If you have type 1 diabetes (insulin dependent diabetes mellitus), do not stop your insulin and continue to get enough carbohydrates.
Če imate sladkorno bolezen tipa 1 (od insulina odvisna sladkorna bolezen), ne nehajte uporabljati insulina in še naprej uživajte dovolj ogljikovih hidratov.
Immediately after delivery, insulin requirements decline rapidly (increased risk of hypoglycaemia).
Takoj po porodu se potreba po insulinu hitro zmanjša (povečano tveganje za hipoglikemijo).
• Do not use your pen past the expiration date printed on the label or for more than 28 days after you first start using the pen.
• Ne uporabljajte svojega peresnika po preteku roka uporabnosti, ki je natisnjen na oznaki ali več kot 28 dni po prvi uporabi peresnika.
ABASAGLAR is injected under the skin.
Zdravilo ABASAGLAR se injicira pod kožo.
• The directions regarding needle handling are not intended to replace local, healthcare professional or institutional policies.
• Navodila za ravnanje z iglami niso namenjena temu, da bi nadomestila lokalne smernice,
Clinical study safety data are not available for children under 2 years.
Kliničnih študij pri otrocih, mlajših od 2 let, ni na voljo.
------ NPH insulin
------ Insulin NPH
If you use more ABASAGLAR than you should
Če ste uporabili večji odmerek zdravila ABASAGLAR, kot bi smeli
• If you do not prime before each injection, you may get too much or too little insulin.
• Če peresnika pred vsakim vbrizgavanjem ne pripravite, je insulina lahko premalo ali preveč.
It should be considered whether it is advisable to drive or operate machines in these circumstances.
V takšnih okoliščinah je treba razmisliti, ali je priporočljivo, da bolnik vozi ali upravlja s stroji.
This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).
To je lahko nevarno v okoliščinah, v katerih sta ti zmožnosti posebno pomembni (npr. pri vožnji avtomobila ali uporabi strojev).
This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia.
To je posebej pomembno pri bolnikih z zmanjšanim ali odsotnim zaznavanjem opozorilnih znakov hipoglikemije in pri tistih, ki imajo pogoste hipoglikemije.
2, rue du Colonel Lilly F-67640 Fegersheim France
2, rue du Colonel Lilly F-67640 Fegersheim Francija
• ABASAGLAR is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms.
• Zdravilo ABASAGLAR se vbrizga pod kožo (subkutano) na področju vašega trebuha, zadnjice, zgornjega dela nog ali zgornjega dela rok.
Selecting your dose
Izbira vašega odmerka
Pharmacokinetics in children aged 2 to less than 6 years with type 1 diabetes mellitus was assessed in one clinical study (see section 5.1).
Študija farmakokinetike pri otrocih s sladkorno boleznijo tipa 1, starih od 2 do manj kot 6 let, je bila izvedena v eni klinični študiji (glejte poglavje 5.1).
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALEC (IZDELOVALCI) BIOLOŠKE UČINKOVINE (UČINKOVIN) IN IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE
Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar.
Sladkorna bolezen je bolezen, pri kateri v telesu ne nastaja dovolj insulina za uravnavanje ravni krvnega sladkorja.
Special care before injection
Posebna previdnost pred injiciranjem
Follow closely the instructions for posology, monitoring (blood and urine tests), diet and physical activity (physical work and exercise) as discussed with your doctor.
Natančno upoštevajte navodila za odmerjanje, nadziranje bolezni (testi krvi in urina), prehrano in telesno dejavnost (telesno delo in telovadbo), ki vam jih je dal zdravnik.
PLEASE READ THESE INSTRUCTIONS BEFORE USE
PRED UPORABO PREBERITE TA NAVODILA
- Do not remove the pen label.
Ne odstranjujte oznake peresnika.
- If you still do not see insulin, change the needle and repeat the priming steps.
- Če še vedno ne vidite insulina, zamenjajte iglo in ponovite korake za aktivacijo.
It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy to prevent adverse outcomes associated with hyperglycaemia.
Nujno je, da bolnice z obstoječim ali gestacijskim diabetesom vso nosečnost vzdržujejo dobro urejenost presnove, da se preprečijo neželeni izidi, povezani s hiperglikemijo.
Read the instructions for use before you start taking ABASAGLAR and each time you get another ABASAGLAR KwikPen.
Preberite Navodila za uporabo, preden začnete uporabljati zdravilo ABASAGLAR in vsakokrat, ko dobite nov peresnik ABASAGLAR KwikPen.
• Skin and allergic reactions at the injection site
• Kožne in alergijske reakcije na mestu injiciranja
Light grey
svetlo siva
Severe allergic reactions to insulins may become life-threatening.
Hude alergijske reakcije na insuline lahko postanejo smrtno nevarne.
Refer to them before using your medicine.
Preberite jih, preden začnete uporabljati svoje zdravilo.
Before taking a medicine ask your doctor if it can affect your blood sugar level and what action, if any, you need to take.
Preden vzamete zdravilo, zdravnika vprašajte, ali lahko vpliva na koncentracijo krvnega sladkorja, ali je v zvezi s tem potrebno kakšno posebno ravnanje in če, kakšno.
Your insulin dose may need to be changed during pregnancy and after giving birth.
Odmerek insulina bo med nosečnostjo in po porodu morda treba spremeniti.
These units are exclusive to insulin glargine and are not the same as IU or the units used to express the potency of other insulin analogues (see section 5.1).
Te enote veljajo izključno za insulin glargin in niso enake mednarodnim enotam (i.e.) ali enotam, ki se uporabljajo za izražanje jakosti drugih insulinskih analogov (glejte poglavje 5.1).
Important information about some of the ingredients of ABASAGLAR
Pomembne informacije o nekaterih sestavinah zdravila ABASAGLAR
After subcutaneous injection in diabetic patients, insulin glargine is rapidly metabolised at the carboxyl terminus of the Beta chain with formation of two active metabolites M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin).
Po subkutanem injiciranju bolnikom s sladkorno boleznijo se insulin glargin hitro presnovi na karboksilnem koncu verige beta; nastaneta aktivna presnovka M1 (21A-Gly-insulin) in M2 (21A-Glydes-30B-Thr-insulin).
• If the dose knob it is hard to push: - Pushing the dose knob more slowly will make it easier to inject.
• Če gumb za odmerjanje težko pritisnete: - morda bo pomagalo, če boste gumb za odmerjanje med injiciranjem pritiskali počasneje
For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available.
Za insulin glargin ni na voljo kliničnih podatkov iz nadzorovanih kliničnih preskušanj od nosečnic, ki so bile izpostavljene zdravilu.
ABASAGLAR is not the insulin of choice for the treatment of diabetic ketoacidosis.
Zdravilo ABASAGLAR ni insulin prve izbire za zdravljenje diabetične ketoacidoze.
- The pen dials 1 unit at a time.
- Peresnik nastavi 1 enoto naenkrat.
Before use:
Pred uporabo:
• Turn the dose knob to select the number of units you need to inject.
Zavrtite gumb za odmerjanje tako, da boste izbrali število enot, ki si jih morate vbrizgati.
• Do not recycle the filled sharps container.
• Polnega vsebnika za ostre odpadke ne reciklirajte.
Light grey with green colour bars
svetlo sive s črtami zelene barve
If you inject your insulin too often at the same skin site, fatty tissue under the skin at this site may either shrink (lipoatrophy, may affect up to 1 in 100 people) or thicken (lipohypertrophy).
Če si insulin prepogosto injicirate na istem mestu kože, se lahko podkožno maščevje na tem mestu bodisi skrči (lipoatrofija, lahko se pojavi pri največ 1 od 100 bolnikov) ali zadebeli (lipohipertrofija).
Very common
Zelo redki
If you have proliferative retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks may cause temporary loss of vision.
Če imate proliferativno retinopatijo (očesno bolezen, povezano s sladkorno boleznijo), lahko huda hipoglikemija povzroči začasno izgubo vida.
Do not use ABASAGLAR KwikPen if it is damaged or not working properly, it has to be discarded and a new KwikPen has to be used.
Ne uporabljajte peresnika ABASAGLAR KwikPen, če je poškodovan ali če ne deluje pravilno; treba ga je zavreči in uporabiti nov peresnik KwikPen.
Changes in strength, brand (manufacturer), type (regular, NPH, lente, long-acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose.
Spremembe jakosti, zaščitne znamke (izdelovalec), tipa (običajni humani insulin, NPH, lente, dolgo delujoči), izvora (živalski, humani, analog humanega insulina) in/ali načina izdelave, lahko posledično vplivajo na spremembo odmerjanja.
Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Dolgoročno izboljšanje glikemične urejenosti zmanjša tveganje za napredovanje diabetične retinopatije.
A new needle must be attached before each use.
Pred vsako uporabo morate pritrditi novo iglo.
Pen Needle Parts (Needles Not Included)
Deli igle peresnika (igle niso priložene)
Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.
Uporabo pioglitazona je potrebno nemudoma ukiniti, v primeru pojava poslabšanja srčnih simptomov.
Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.
Večina manjših reakcij na insuline na mestu injiciranja običajno mine v nekaj dneh do nekaj tednih.
Glucose Utilization Rate* (mg/kg/min)
Čas (h) po subkutanem injiciranju zraba glukoze Hitrost* (mg/kg/min)
Push the dose knob in until it stops, and “0” is seen in the dose window.
Gumb za odmerjanje pritiskajte navznoter, dokler se ne zaustavi in v okencu za odmerjanje ne zagledate številke 0.
For storage conditions after first opening of this medicinal product, see section 6.3.
Za pogoje shranjevanja po prvem odprtju zdravila glejte poglavje 6.3.
What ABASAGLAR is and what it is used for What you need to know before you use ABASAGLAR How to use ABASAGLAR
Kaj je zdravilo ABASAGLAR in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo ABASAGLAR Kako uporabljati zdravilo ABASAGLAR
Mean dose of insulin glargine by study end was 0.42 U/kg.
Povprečni odmerek insulina glargin do konca študije je bil 0,42 enote/kg.
Glycohaemoglobin and glucose variabilities were comparable in both treatment groups.
Glikirani hemoglobin in variabilnost glukoze sta bila v obeh skupinah primerljiva.
Your blood sugar level may either rise or fall if you take:
Krvni sladkor se vam lahko zviša ali zniža, če jemljete:
Insulin overdose may lead to severe and sometimes long-term and life-threatening hypoglycaemia.
Preveliko odmerjanje insulina lahko povzroči hudo ter včasih dolgotrajno in smrtno nevarno hipoglikemijo.
- If you do not see “0” in the dose window, do not redial.
-Če v okencu za prikaz odmerka ne vidite številke »0«, ne nastavite odmerka znova.
Insulin glargine is metabolised into 2 active metabolites M1 and M2 (see section 5.2).
Insulin glargin se presnovi v 2 aktivna presnovka, M1 in M2 (glejte poglavje 5.2).
If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema.
Pri uporabi te kombinacije je treba pri bolnikih opazovati znake in simptome srčnega popuščanja, pridobivanje teže in prisotnost edema.
Giving your injection
Dajanje injekcije
The use of ABASAGLAR may be considered during pregnancy, if clinically needed.
Med nosečnostjo lahko pride v poštev uporaba zdravila ABASAGLAR, če je klinično potrebna.
• If you cannot remove the pen cap, gently twist the cap back and forth, and then pull the cap straight off.
• Če ne morete odstraniti pokrovčka peresnika, nežno zavrtite pokrovček nazaj in naprej in ga nato potegnite naravnost navzdol.
In patients with type 2 diabetes mellitus, ABASAGLAR can also be given together with orally active antidiabetic medicinal products.
Pri bolnikih z diabetesom mellitusom tipa 2 je mogoče zdravilo ABASAGLAR uporabljati tudi skupaj s peroralnimi antidiabetičnimi zdravili.
Choose your injection site.
Izberite mesto injiciranja.
Store below 30 º C.
Shranjujte pri temperaturi do 30 º C.
Pentamidine (used to treat some infections caused by parasites) may cause hypoglycaemia which may sometimes be followed by hyperglycaemia.
Pentamidin (uporablja se za zdravljenje nekaterih okužb, ki jih povzročijo zajedavci) lahko povzroči hipoglikemijo, ki ji včasih sledi hiperglikemija.
There were no differences between insulin glargine and standard care for the two coprimary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome.
Med insulinom glargin in standardnim zdravljenjem ni bilo razlik glede dveh primarnih izidov, glede katere koli komponente opazovanega dogodka, ki je vključevala te izide, glede celokupne smrtnosti in glede sestavljenega mikrovaskularnega izida.
If you have any questions or problems with your ABASAGLAR KwikPen, contact your healthcare professional for assistance.
Če imate vprašanja ali težave z vašim injekcijskim peresnikom ABASAGLAR KwikPen, se za pomoč obrnite na svojega zdravstvenega delavca.
* Insulin glargine is produced by recombinant DNA technology in Escherichia coli.
*Insulin glargin je pridobljen s tehnologijo rekombinantne DNA iz bakterij Escherichia coli.
Not all of these pens may be marketed in your country.
V vaši državi na trgu morda ni vseh navedenih peresnikov.
Other medicines and ABASAGLAR
Druga zdravila in zdravilo ABASAGLAR
Switch from other insulins to ABASAGLAR
Prehod z drugih insulinov na zdravilo ABASAGLAR
Stomach pain, fast and deep breathing, sleepiness or even loss of consciousness may be signs of a serious condition (ketoacidosis) resulting from lack of insulin.
zaspanost ali celo izguba zavesti pa so lahko znaki resnega stanja (ketoacidoze), ki se pojavi zaradi pomanjkanja insulina.
It is unknown whether insulin glargine is excreted in human milk.
Ni znano, ali se insulin glargin izloča v materino mleko.
Pharmacotherapeutic group: Drugs used in diabetes, insulins and analogues for injection, long-acting.
Farmakoterapevtska skupina: Zdravila za zdravljenje diabetesa, insulini za injiciranje z dolgotrajnim delovanjem in analogi.
Hypoglycaemia (low blood sugar) can be very serious and is very common with insulin treatment (may affect more than 1 in 10 people).
Hipoglikemija (nizka koncentracija krvnega sladkorja) je lahko zelo resna in je pri zdravljenju z insulinom zelo pogosta (pojavi se lahko pri več kot 1 od 10
Change the injection site with each injection to help prevent these skin changes.
Mesto injiciranja pri vsaki injekciji zamenjajte, da preprečite te kožne spremembe.
What you need to know before you use ABASAGLAR Do not use ABASAGLAR
Kaj morate vedeti, preden boste uporabili zdravilo ABASAGLAR Ne uporabljajte zdravila ABASAGLAR
Do not try to inject your insulin by turning the dose knob.
Ne poskušajte si injicirati insulina z obračanjem gumba za odmerjanje.
This medicine contains less than 1 mmol (23 mg) sodium per dose, which means it is essentially ‘sodium-free'.
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni “brez natrija”.
Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Insulin in njegovi analogi znižujejo koncentracijo glukoze v krvi s spodbujanjem perifernega privzema glukoze, zlasti v skeletnem mišičju in maščevju, ter z zaviranjem tvorbe glukoze v jetrih.
• You can give from 1 to 6080 units in a single injection.
• Z eno injekcijo lahko dozirate od 1 do 60 80 enot.
Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angiooedema, bronchospasm, hypotension and shock, and may be life-threatening.
Takšne reakcije na insulin (tudi na insulin glargin) ali pomožne snovi so lahko povezane tudi npr. z generaliziranimi kožnimi reakcijami, angioedemom, bronhospazmom, hipotenzijo in šokom ter so lahko smrtno nevarne.
In clinical studies, subgroup analyses based on age and gender did not indicate any difference in safety and efficacy in insulin glargine-treated patients compared to the entire study population.
Analize podskupin po starosti in spolu v kliničnih študijah niso pokazale razlik v varnosti in učinkovitosti pri bolnikih, zdravljenih z insulinom glargin, v primerjavi s celotno raziskovano populacijo.
As with all insulins, the time course of action of insulin glargine may be affected by physical activity and other variables.
Na časovni potek delovanja insulina glargin lahko, tako kot pri vseh insulinih, vplivajo telesna dejavnost in drugi spremenljivi dejavniki.
If the insulin pen is damaged or not working properly (due to mechanical defects) it has to be discarded, and a new insulin pen has to be used.
Če je insulinski peresnik poškodovan ali če ne deluje pravilno (zaradi mehanskih okvar), ga morate zavreči in uporabiti nov insulinski peresnik.
Store below 30 º C. Do not refrigerate or freeze.
Shranjujte pri temperaturi do 30 º C. Ne shranjujte v hladilniku in ne zamrzujte.
Hold the dose knob in and count to 5 slowly.
Gumb za odmerjanje pritiskajte navznoter in počasi štejte do pet.
• Pull off the inner needle shield and throw it away.
• Odstranite zaščito notranje igle in jo zavrzite.
Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.
Intravenska aplikacija običajnega subkutanega odmerka lahko povzroči hudo hipoglikemijo.
The primary aim of demonstrating non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and there was a trend to an increase of hypoglycaemic events with insulin glargine [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)].
Primarni cilj, dokazati neinferiornost insulina glargin v primerjavi z insulinom NPH v zvezi z hipoglikemijami, ni bil dokazan - opazen je bil trend povečanja hipoglikemičnih dogodkov z insulinom glargin [razmerje insulin glargin : NPH (95 % IZ) = 1,18 (0,97-1,44)].
In case of insufficient glucose control or a tendency to hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiperglikemijam ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustrezno tehniko injiciranja in vse druge pomembne dejavnike.
ABASAGLAR should look clear and colourless.
Zdravilo ABASAGLAR mora biti na pogled bistro in brezbarvno.
Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim, France.
Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim, Francija.
ABASAGLAR is a biosimilar medicinal product.
Zdravilo ABASAGLAR je biološko podobno zdravilo.
EXP Discard 28 days after first use.
EXP Peresnik zavrzite 28 dni po prvi uporabi.
Combination of ABASAGLAR with pioglitazone
Kombinacija zdravila ABASAGLAR in pioglitazona
Very rare side-effects (may affect up to1 in 10,000 people) In very rare cases, dysgeusia (taste disorders) and myalgia (muscular pain) can occur.
Zelo redko poročani neželeni učinki (pojavijo se lahko pri največ 1 od 10.000 bolnikov) V zelo redkih primerih se lahko pojavita disgevzija (motnje okušanja) in mialgija (bolečine v mišicah).
In a randomised, controlled clinical study, paediatric patients (age range 6 to 15 years) with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal.
Pediatrična populacija V randomizirani, kontrolirani klinični študiji so pediatrične bolnike (stare od 6 do 15 let) s sladkorno boleznijo tipa 1 (n=349) 28 tednov zdravili z bazalno-bolusnim insulinskim režimom, pri katerem je bil pred vsakim obrokom uporabljen navadni humani insulin.
Keep Throw Away
Obdržite Zavržite
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure.
Pri nekaterih bolnikih z dolgotrajno sladkorno boleznijo tipa 2 in srčno boleznijo ali predhodno kapjo, ki so se zdravili s pioglitazonom in inzulinom, je prišlo do razvoja srčnega popuščanja.
Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections
natrijev hidroksid (za prilagoditev pH) voda za injekcije
Intercurrent illness requires intensified metabolic monitoring.
V primeru sočasnih bolezni je potreben intenzivnejši nadzor presnove.
Complaints of injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults.
O pritožbah zaradi reakcij na mestu injiciranja (bolečina na mestu injiciranja, reakcija na mestu injiciranja) in kožnih reakcij (izpuščaj, urtikarija) so poročali relativno bolj pogosto pri otrocih in mladostnikih, starih 18 let ali manj, kot pri odraslih bolnikih.
Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).
Nemudoma obvestite svojega zdravnika, če opazite znake srčnega popuščanja, kot so neobičajno primanjkovanje zraka pri vdihovanju ali naglo povečanje telesne mase ali lokalizirano otekanje (edemi).
Switch from insulin glargine 300 units/ml to ABASAGLAR ABASAGLAR and Toujeo (insulin glargine 300 units/ml) are not bioequivalent and are not directly interchangeable.
Prehod z insulina glargina 300 enot/ml na zdravilo ABASAGLAR Zdravili ABASAGLAR in Toujeo (insulin glargin 300 enot/ml) nista bioekvivalentni zdravili in nista neposredno medsebojno zamenljivi.
Concentrations were thus consistent with the time profile of the pharmacodynamic activity of insulin glargine.
Koncentracija se je torej skladala s časovnim potekom farmakodinamičnega delovanja insulina glargin.
Only use needles that are compatible for use with ABASAGLAR KwikPen (see “ABASAGLAR KwikPen Instructions for Use”).
Uporabljajte le igle, ki so primerne za uporabo s peresnikom ABASAGLAR KwikPen (glejte Navodila za uporabo peresnika ABASAGLAR KwikPen).
Throw the pen away and get a new pen.
Zavrzite peresnik in vzemite novega.
A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine.
Večja količina podatkov o nosečnicah (več kot 1.000 izidov nosečnosti) ne kaže nobenih posebnih neželenih učinkov insulina glargin na nosečnost; prav tako ne kaže, da bi insulin glargin povzročal posebne malformacije, fetotoksične učinke ali toksične učinke na novorojenčka.